Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies.

Next Previous
Trial Profile

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Busulfan; Melphalan
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Leukaemia; Lymphoma; Multiple myeloma; Myeloid leukaemia; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results (n=28) assessing the results on 28 patients who received the TMI-based transplant, whereas among the remaining 3, 1 had not started the conditioning yet and 2 became ineligible due to progression of disease and deterioration of performance status, respectively were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 20 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jan 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top